Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

PALI vs NMAD: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PALI Wins Head-to-Head Institutional Verdict (3–1 across 6 Pillars · 7–2 Matrix Metrics)

PALI Overall Winner 6-Pillar Tally: PALI 3 – 1 NMAD (2 Tie) Matrix Metrics: PALI 7 – 2 NMAD

As of Nov 20, 2026, Palisade Bio, Inc. (PALI) is the stronger overall head-to-head candidate over NMAD (NMAD) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PALI carries a Unified Composite Score of 39.3/100 (SELL) at $0.84 (N/M Forward P/E, -9625.4% operating margin), whereas NMAD carries 47.9/100 (HOLD) at $2.56 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While NMAD currently prints a higher short-term Unified Composite Score (47.9/100 HOLD vs. PALI 39.3/100 SELL), PALI captures the overall institutional head-to-head verdict (7–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-9625.4% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: PALI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.4); meanwhile NMAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About PALI vs NMAD
PALI NASDAQ Head-to-Head Winner
Palisade Bio, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$0.84
-9.24% 1D
Market Cap $166.1M
TTM Revenue $500,000
Forward P/E N/M
Beta / 30D Vol 1.44β · 70% Vol
Unified Composite Score
39.3 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.7%), weak momentum, RSI 24
RSI-14: 24.4 · SMA20: $1.12 · SMA50: $1.37
NMAD US Equity
NMAD
Institutional Equity
$2.56
+13.53% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.52β · 173% Vol
Unified Composite Score
47.9 / 100 HOLD
Tech 43.0 Fund 49.0 Flow 50.0 Mom 70.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -6.8%), weak momentum, RSI 38
RSI-14: 38.1 · SMA20: $3.37 · SMA50: $3.65

6-Pillar Scorecard Institutional Category Breakdown (PALI 3 – 1 NMAD)

Columns: Metric · PALI · NMAD
1. Valuation Multiples PALI
Forward P/E N/M N/M
Trailing P/E 1.0x N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale PALI
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $500,000 N/A
Market Cap $166.1M N/A
3. Profitability & Quality PALI
Gross Margin 100.0% N/A
Operating Margin -9625.4% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -75.6% N/A
4. Balance Sheet & Cash Flow NMAD
Cash Generation (TTM) -$12M N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $0.65 Book/Sh · -75.6% ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: PALI (7) vs NMAD (2)
Institutional Metric PALI NMAD Criterion Row Edge
Market Capitalization
Scale
$166.1M N/A Larger Scale PALI
Trailing P/E Ratio
Valuation
1.0x N/M Lower Multiple PALI
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth PALI
Operating Margin (TTM)
Profitability
-9625.4% N/A Higher Margin PALI
Net Profit Margin
Profitability
0.0% N/A Higher Margin PALI
Return on Equity (ROE)
Capital Efficiency
-75.6% N/A Higher ROE PALI
52-Week Range Position
Momentum
0% ($1–$3) 8% ($2–$8) Stronger Trend NMAD
Beta / 30D Volatility
Risk Regime
1.44β · 70% Vol 0.52β · 173% Vol Lower Realized Risk PALI
Unified Institutional Score
Composite Signal
39.3 / 100 (SELL) 47.9 / 100 (HOLD) Higher Composite NMAD
Trailing 12M Revenue (USD)
Operating Scale
$500,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
100.0% N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$12M ($0.65 Book/Sh · -75.6% ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NMAD +8.9 pp
PALI: -37.79% · NMAD: -28.89%
3M Horizon NMAD +19.9 pp
PALI: -58.21% · NMAD: -38.31%
6M Horizon PALI +6.29 pp
PALI: -58.83% · NMAD: -65.12%
1Y Horizon PALI +6.29 pp
PALI: -58.83% · NMAD: -65.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on PALI vs NMAD. Trailing 12-month operating profitability (PALI -9625.4% vs NMAD N/A) and valuation multiples (PALI N/M vs NMAD N/M Forward P/E) are benchmarked directly in Pillar 4 below.

PALI ADR TTM Benchmark FX-Normalized USD
TTM Revenue$500,000
Gross Margin100.0%
Op. Margin-9625.4%
ROE / Fwd P/E-75.6% · N/M
NMAD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
PALI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact PALI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NMAD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NMAD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
PALI Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $166.1M market capitalization and -9625.4% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NMAD Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ PALI vs NMAD Key Questions & Quantitative Answers

As of Nov 20, 2026, Palisade Bio, Inc. (PALI) is the stronger overall head-to-head candidate over NMAD (NMAD) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). PALI carries a Unified Composite Score of 39.3/100 (SELL) at $0.84 (N/M Forward P/E, -9625.4% operating margin), whereas NMAD carries 47.9/100 (HOLD) at $2.56 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While NMAD currently prints a higher short-term Unified Composite Score (47.9/100 HOLD vs. PALI 39.3/100 SELL), PALI captures the overall institutional head-to-head verdict (7–2 matrix metrics and 3–1 across the 6 pillars) due to superior fundamental profitability (-9625.4% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: PALI is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 24.4); meanwhile NMAD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 38.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PALI leads the Growth & Scale pillar: PALI posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $500,000 TTM revenue (100.0% gross margin, -9625.4% operating margin), compared with NMAD at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, PALI generates $500,000 in USD-normalized revenue versus N/A for NMAD. In operating R&D and SG&A reinvestment, PALI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NMAD.

PALI screens cheaper on headline valuation multiples. PALI trades at N/M Forward P/E, 1.0x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas NMAD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against PALI (-75.6% ROE) versus NMAD (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, PALI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.44β · 70% Vol realized risk). By comparison, NMAD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.52β · 173% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.